Merck reorganized its human health business into a standalone oncology unit and a separate specialty, pharma and infectious disease division as Keytruda’s U.S. loss of exclusivity approaches. The oncology unit will centralize management of Keytruda and other cancer assets; Merck named Jannie Oosthuizen to lead oncology and tapped Sanofi veteran Brian Foard to run the specialty business. The move aims to sharpen launch execution and commercial focus across divergent portfolios—oncology’s blockbuster legacy versus non‑cancer growth drivers like Winrevair and Januvia—while positioning new leadership to manage product lifecycles as Keytruda faces intense competitive and patent pressures in the coming years.